FDA Clears Dexcom G7 Continuous Glucose Monitoring System for Diabetes

The FDA has cleared Dexcom’s G7 continuous glucose monitoring system for both Type 1 and Type 2 diabetes patients two years and older.

The G7 device is 60 percent smaller than the G6 version and features a redesigned and simplified mobile app and a 30-minute sensor warmup, the fastest available for continuous glucose monitoring tools, the company said.

Dexcom said it is “working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as possible.”

The company plans on launching the Dexcom G7 device in the U.S. starting in early 2023.